You are here
BioInvent Expands U.S. Patent Protection for its F.I.R.S.T.(TM) Platform
LUND, March 13, 2019 /PRNewswire/ -- BioInvent International AB (OMXS: BINV) announces today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance, informing the company that a patent application relevant to its F.I.R.S.T.™ platform has been allowed and can proceed to grant. The patent is expected to be issued once BioInvent has responded to the Notice. It covers methods for differential biopanning.
This patent, once issued, strengthens the protection in the US. .for BioInvent's unique, function-based F.I.R.S.T.™ platform, which allows for simultaneous identification of clinically relevant target structures and matching antibodies.
The now allowed application is a so called continuation application based on a US patent that was granted in 2013. A similar patent was granted some years earlier by the European patent office, and it is valid in 20 European countries.
BioInvent International AB (OMXS: BINV) is focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies to treat cancer. The Company's lead program is BI-1206, currently in Phase l/ll for non-Hodgkin lymphoma and chronic lymphatic leukemia. BioInvent's pre-clinical portfolio is focused on targeting key immune suppressive cells and pathways of the tumor microenvironment, including regulatory T cells, tumor-associated myeloid cells and mechanisms of antibody drug-resistance. The Company has a strategic research collaboration with Pfizer Inc., and partnerships with Transgene, Bayer Pharma, Daiichi Sankyo, and Mitsubishi Tanabe Pharma. BioInvent generates near term revenues from its fully integrated manufacturing unit producing antibodies for third parties for research through to late-stage clinical trials. More information is available at www.bioinvent.com.
The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.
This information is information that BioInvent International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 1.00 p.m. CET, on March 13, 2019.
For further information, please contact:
Martin Welschof, CEO
Hans Herklots, LifeSci Advisors
BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Sölvegatan 41
Mailing address: 223 70 LUND
Phone: +46 (0)46 286-85-50
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Press release (PDF)